Clarius Group LLC Buys 2,968 Shares of Boston Scientific Corporation (NYSE:BSX)

Clarius Group LLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 34.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,493 shares of the medical equipment provider's stock after buying an additional 2,968 shares during the quarter. Clarius Group LLC's holdings in Boston Scientific were worth $1,159,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in BSX. Colonial Trust Co SC raised its position in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV bought a new stake in Boston Scientific during the 4th quarter valued at about $25,000. Sunbeam Capital Management LLC bought a new stake in Boston Scientific during the 4th quarter valued at about $26,000. Ameriflex Group Inc. purchased a new position in Boston Scientific in the fourth quarter worth about $31,000. Finally, Fairway Wealth LLC bought a new position in shares of Boston Scientific in the fourth quarter worth approximately $36,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the transaction, the chief executive officer now owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This represents a 9.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 411,970 shares of company stock valued at $42,406,693. Company insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BSX. Truist Financial raised their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Citigroup reiterated a "buy" rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday. Evercore ISI boosted their price target on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Finally, Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Twenty-two analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $116.09.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $101.72 on Wednesday. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.17. The firm has a market capitalization of $150.49 billion, a price-to-earnings ratio of 74.25, a price-to-earnings-growth ratio of 2.62 and a beta of 0.68. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The firm has a 50 day moving average of $101.35 and a 200 day moving average of $98.89.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company's revenue was up 20.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.56 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.